Loading...
•
Jun 30, 2023
Vanda Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
Vanda Pharmaceuticals reported a total revenue of $46.1 million, driven by net product sales from HETLIOZ® and Fanapt®. Net income for the quarter was $1.5 million. The company is facing challenges with HETLIOZ® due to the at-risk launch of a generic version in the U.S.
Total revenues for Q2 2023 were $46.1 million.
HETLIOZ® net product sales decreased by 47% to $22.0 million due to generic competition.
Fanapt® net product sales increased by 4% to $24.1 million.
Net income for Q2 2023 was $1.5 million.
Revenue by Segment
Forward Guidance
Vanda is unable to provide 2023 financial guidance due to uncertainties surrounding the U.S. market for HETLIOZ® because of ongoing patent litigation and the at-risk launch of a generic version. HETLIOZ® net product sales will likely decline in future periods.
Challenges Ahead
- Uncertainties surrounding the U.S. market for HETLIOZ®.
- Ongoing HETLIOZ® patent litigation.
- At-risk launch of a generic version of HETLIOZ®.
- HETLIOZ® net product sales will likely decline in future periods.
- Company is unable to provide 2023 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...